Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
J Pharm Biomed Anal ; 169: 279-287, 2019 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-30884326

RESUMEN

Ebracteolatain A is a phloroglucinol derivative from the root of Euphorbia ebracteolata Hayata, a Traditional Chinese Medicine also known as Langdu. It has been shown to have good inhibitory effects in breast cancer cells. In this study, a simple, rapid, sensitive, and specific ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated to study the pharmacokinetics (PKs) and tissue distribution of Ebracteolatain A in rats. Ebracteolatain A and Magnolol (internal standard) were extracted by the simple protein precipitation extraction technique using methanol as the precipitating solvent. Chromatographic separation was performed using the Agilent Poroshell 120 EC-C18 column with a mobile phase of acetonitrile:0.1% formic acid (70:30, v/v). The protonated analyte was quantitated in negative ionization by MS/MS via multiple reaction monitoring mode. The assay exhibited a linear dynamic range of 2-2000 ng/mL for Ebracteolatain A in biological samples. The lower limit of quantitation was 2 ng/mL. Non-compartmental PK parameters indicated that Ebracteolatain A was well absorbed into the systemic circulation. The absolute bioavailability of Ebracteolatain A was greater when administered by intraperitoneal administration than by oral administration. The tissue distribution study showed that Ebracteolatain A was distributed in the heart, liver, spleen, lung, kidney, brain, stomach, intestine, uterus, ovary, and breast after intravenous injection. The results of this study further our understanding of the in vivo anti-cancer activity of Ebracteolatain A, and shed light on pharmacological strategies that may be useful for the development of novel breast cancer therapeutics.


Asunto(s)
Antineoplásicos/farmacocinética , Floroglucinol/análogos & derivados , Administración Oral , Animales , Disponibilidad Biológica , Neoplasias de la Mama/tratamiento farmacológico , Cromatografía Líquida de Alta Presión/métodos , Femenino , Inyecciones Intravenosas/métodos , Límite de Detección , Medicina Tradicional China/métodos , Floroglucinol/farmacocinética , Ratas , Ratas Sprague-Dawley , Espectrometría de Masas en Tándem/métodos , Distribución Tisular
2.
Clin Pharmacol Ther ; 106(2): 432-440, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-30739325

RESUMEN

Hypericum perforatum L. (St. John's wort) is used to treat mild-to-moderate depression. Its potential safety risks are pharmacokinetic drug interactions via cytochrome P450 (CYP) enzymes and P-glycoprotein, presumably caused by hyperforin. In a phase I, open-label, nonrandomized, single-sequence study, the low-hyperforin Hypericum extract Ze 117 was investigated using a drug cocktail in 20 healthy volunteers. No pharmacokinetic interactions of Ze 117 were observed for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, and P-glycoprotein. Area under the curve (AUC) and peak plasma concentration (Cmax ) of the used probe drugs showed 90% confidence intervals (CIs) of the geometric mean ratios of the drugs taken together with Ze 117 vs. probe drug alone, well within the predefined bioequivalence range of 80-125%. Though Ze 117 did not induce dextromethorphan metabolism by CYP2D6, it weakly increased dextromethorphan AUC ratio (mean 147.99, 95% CI 126.32-173.39) but not the corresponding metabolic ratio. Ze 117 does not show clinically relevant pharmacokinetic interactions with important CYPs and P-glycoprotein.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Sistema Enzimático del Citocromo P-450 , Interacciones Farmacológicas , Floroglucinol/análogos & derivados , Extractos Vegetales/farmacocinética , Terpenos/farmacocinética , Adulto , Área Bajo la Curva , Sistema Enzimático del Citocromo P-450/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Dextrometorfano/farmacocinética , Relación Dosis-Respuesta a Droga , Femenino , Voluntarios Sanos , Humanos , Hypericum/metabolismo , Masculino , Floroglucinol/farmacocinética , Psicotrópicos/farmacocinética
3.
Clin Pharmacokinet ; 58(7): 911-926, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-30675694

RESUMEN

BACKGROUND AND OBJECTIVES: Herb-drug interactions with St John's wort (SJW) have been widely studied in numerous clinical studies. The objective of this study was to develop and evaluate a physiologically based pharmacokinetic (PBPK) model for hyperforin (the constituent of SJW responsible for interactions), which has the potential to provide unique insights into SJW interactions and allow prediction of the likely extent of interactions with SJW compared to published interaction reports. METHODS: A PBPK model of hyperforin accounting for the induction of cytochrome P450 (CYP) 3A, CYP2C9 and CYP2C19 was developed in the Simcyp® Simulator (version 17) and verified using published, clinically observed pharmacokinetic data. The predictive performance of this model based on the prediction fold-difference (expressed as the ratio of predicted and clinically observed change in systemic exposure of drug) was evaluated across a range of CYP substrates. RESULTS: The verified PBPK model predicted the change in victim drug exposure due to the induction by SJW (expressed as area under the plasma concentration-time curve (AUC) ratio) within 1.25-fold (0.80-1.25) of that reported in clinical studies. The PBPK simulation indicated that the unbound concentration of hyperforin in the liver was far lower than in the gut (enterocytes). Simulations revealed that induction of intestinal CYP enzymes by hyperforin was found to be more pronounced than the corresponding increase in liver CYP activity (15.5- vs. 1.1-fold, respectively, at a hyperforin dose of 45 mg/day). CONCLUSION: In the current study, a PBPK model for hyperforin was successfully developed, with a predictive capability for the interactions of SJW with different CYP3A, CYP2C9 and CYP2C19 substrates. This PBPK model is valuable to predict the extent of herb-drug interactions with SJW and help design the clinical interaction studies, particularly for new drugs and previously unstudied clinical scenarios.


Asunto(s)
Alprazolam/farmacocinética , Antineoplásicos/farmacocinética , Interacciones de Hierba-Droga , Hypericum , Mesilato de Imatinib/farmacocinética , Midazolam/farmacocinética , Modelos Biológicos , Floroglucinol/análogos & derivados , Terpenos/farmacocinética , Adulto , Simulación por Computador , Citocromo P-450 CYP2C19/metabolismo , Citocromo P-450 CYP2C9/metabolismo , Citocromo P-450 CYP3A/metabolismo , Femenino , Humanos , Mucosa Intestinal/metabolismo , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Floroglucinol/farmacocinética
4.
J Nat Prod ; 78(8): 2029-35, 2015 Aug 28.
Artículo en Inglés | MEDLINE | ID: mdl-26287496

RESUMEN

Tetrahydrohyperforin (IDN-5706) is a semisynthetic derivative of hyperforin, one of the main active components of Hypericum perforatum extracts. It showed remarkable positive effects on memory and cognitive performances in wild-type mice and in a transgenic mouse model of Alzheimer's disease, but little was known about the concentrations it can reach in the brain. The investigations reported herein show that repeated treatment of mice with tetrahydrohyperforin (20 mg/kg intraperitoneally, twice daily for 4 days and once on the fifth day) results in measurable concentrations in the brain, up to 367 ng/g brain (∼700 nM) 6 h after the last dose; these concentrations have significant effects on synaptic function in hippocampal slices. The other main finding was the identification and semiquantitative analysis of tetrahydrohyperforin metabolites. In plasma, three hydroxylated/dehydrogenated metabolites were the largest (M1-3) and were also formed in vitro on incubation of tetrahydrohyperforin with mouse liver microsomes; the fourth metabolite in abundance was a hydroxylated/deisopropylated derivative (M13), which was not predicted in vitro. These metabolites were all detected in the brain, with peak areas from 10% (M1) to ∼1.5% (M2, M3, and M13) of the parent compound. In summary, repeated treatment of mice with tetrahydrohyperforin gave brain concentrations that might well underlie its central pharmacological effects. We also provide the first metabolic profile of this compound.


Asunto(s)
Encéfalo/efectos de los fármacos , Hypericum/química , Floroglucinol/análogos & derivados , Terpenos/farmacocinética , Enfermedad de Alzheimer/tratamiento farmacológico , Animales , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Hipocampo/metabolismo , Ratones , Microsomas Hepáticos , Estructura Molecular , Floroglucinol/administración & dosificación , Floroglucinol/química , Floroglucinol/farmacocinética , Terpenos/administración & dosificación , Terpenos/química
5.
Phytother Res ; 28(5): 643-55, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-23897801

RESUMEN

Hypericum perforatum (HP) belongs to the Hypericaceae family and is one of the oldest used and most extensively investigated medicinal herbs. The medicinal form comprises the leaves and flowering tops of which the primary ingredients of interest are naphthodianthrones, xanthones, flavonoids, phloroglucinols (e.g. hyperforin), and hypericin. Although several constituents elicit pharmacological effects that are consistent with HP's antidepressant activity, no single mechanism of action underlying these effects has thus far been found. Various clinical trials have shown that HP has a comparable antidepressant efficacy as some currently used antidepressant drugs in the treatment of mild/moderate depression. Interestingly, low-hyperforin-content preparations are effective in the treatment of depression. Moreover, HP is also used to treat certain forms of anxiety. However, HP can induce various cytochrome P450s isozymes and/or P-glycoprotein, of which many drugs are substrates and which are the main origin of HP-drug interactions. Here, we analyse the existing evidence describing the clinical consequence of HP-drug interactions. Although some of the reported interactions are based on findings from in vitro studies, the clinical importance of which remain to be demonstrated, others are based on case reports where causality can, in some cases, be determined to reveal clinically significant interactions that suggest caution, consideration, and disclosure of potential interactions prior to informed use of HP.


Asunto(s)
Interacciones de Hierba-Droga , Hypericum/química , Extractos Vegetales/farmacología , Plantas Medicinales/química , Antracenos , Antidepresivos/farmacología , Antivirales/farmacología , Depresión/tratamiento farmacológico , Humanos , Perileno/análogos & derivados , Perileno/farmacocinética , Floroglucinol/análogos & derivados , Floroglucinol/farmacocinética , Extractos Vegetales/uso terapéutico , Terpenos/farmacocinética
6.
Planta Med ; 78(18): 1932-8, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23150076

RESUMEN

Nonsteroidal anti-inflammatory drug intake is associated with a high prevalence of gastrointestinal side effects, and severe cardiovascular adverse reactions challenged the initial enthusiasm in cyclooxygenase-2 inhibitors. Recently, it was shown that myrtucommulone, the active ingredient of the Mediterranean shrub Myrtus communis, dually and potently inhibits microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase, suggesting a substantial anti-inflammatory potential. However, one of the most important prerequisites for the anti-inflammatory effects in vivo is sufficient bioavailability of myrtucommulone. Therefore, the present study was aimed to determine the permeability and metabolic stability in vitro as well as the systemic exposure of myrtucommulone in rats. Permeation studies in the Caco-2 model revealed apparent permeability coefficient values of 35.9 ·â€Š10⁻6 cm/s at 37 °C in the apical to basolateral direction, indicating a high absorption of myrtucommulone. In a pilot rat study, average plasma levels of 258.67 ng/mL were reached 1 h after oral administration of 4 mg/kg myrtucommulone. We found that myrtucommulone undergoes extensive phase I metabolism in human and rat liver microsomes, yielding hydroxylated and bihydroxylated as well as demethylated metabolites. Physiologically-based pharmacokinetic modeling of myrtucommulone in the rat revealed rapid and extensive distribution of myrtucommulone in target tissues including plasma, skin, muscle, and brain. As the development of selective microsomal prostaglandin E2 synthase-1 inhibitors represents an interesting alternative strategy to traditional nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for the treatment of chronic inflammation, the present study encourages further detailed pharmacokinetic investigations on myrtucommulone.


Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Inhibidores de la Lipooxigenasa/administración & dosificación , Inhibidores de la Lipooxigenasa/farmacocinética , Microsomas Hepáticos/metabolismo , Myrtus/química , Floroglucinol/análogos & derivados , Administración Oral , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/metabolismo , Antiinflamatorios no Esteroideos/farmacocinética , Araquidonato 5-Lipooxigenasa/efectos de los fármacos , Disponibilidad Biológica , Células CACO-2 , Estabilidad de Medicamentos , Humanos , Oxidorreductasas Intramoleculares/antagonistas & inhibidores , Inhibidores de la Lipooxigenasa/química , Masculino , Estructura Molecular , Permeabilidad , Floroglucinol/administración & dosificación , Floroglucinol/química , Floroglucinol/metabolismo , Floroglucinol/farmacocinética , Prostaglandina-E Sintasas , Ratas , Ratas Wistar
7.
Eur J Pharm Sci ; 42(3): 273-84, 2011 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-21168483

RESUMEN

The metabolism of hyperforin, one of the pharmacologically most active components of St. John's wort (Hypericum perforatum), was characterized in vitro using human liver microsomes and recombinant heterologously expressed P450 enzymes. A total of 57 hyperforin metabolites were detected. Of those, six were identified as monohydroxylations (M1-M6), while the others were formed via two or more hydroxylation reactions, via dehydrogenation, or by combinations of these reactions. A combined approach of cDNA-expressed recombinant CYPs, CYP-selective chemical inhibitors and correlation with CYP-specific marker activities indicated a central role of the CYP2C and CYP3A families in the metabolism of hyperforin. In addition, hyperforin was found to inhibit CYP2D6 and CYP3A4 model activities quite potently.


Asunto(s)
Hypericum/química , Microsomas Hepáticos/metabolismo , Floroglucinol/análogos & derivados , Terpenos/farmacocinética , Compuestos Bicíclicos con Puentes/farmacocinética , Cromatografía Liquida , Sistema Enzimático del Citocromo P-450/metabolismo , Humanos , Hidroxilación , Microsomas Hepáticos/enzimología , Floroglucinol/farmacocinética , Espectrometría de Masas en Tándem
8.
Drug Metab Dispos ; 38(1): 16-24, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19833845

RESUMEN

Monkeys have been proposed as an animal model to predict the magnitude of human clinical drug-drug interactions caused by CYP3A4 enzyme induction. To evaluate whether the cynomolgus monkey can be an effective in vivo model, human CYP3A4 inducers were evaluated both in vitro and in vivo. First, a full-length pregnane X receptor (PXR) was cloned from the cynomolgus monkey, and the sequence was compared with those of rhesus monkey and human PXR. Cynomolgus and rhesus monkey PXR differed by only one amino acid (A68V), and both were highly homologous to human PXR (approximately 96%). When the transactivation profiles of 30 compounds, including known inducers of CYP3A4, were compared between cynomolgus and human PXR, a high degree of correlation with EC(50) values was observed. These results suggest that cynomolgus and human PXR respond in a similar fashion to these ligands. Second, two known human CYP3A4 inducers, rifampicin and hyperforin, were tested in monkey and human primary hepatocytes for induction of CYP3A enzymes. Both monkey and human hepatocytes responded similarly to the inducers and resulted in increased RNA and enzyme activity changes of CYP3A8 and CYP3A4, respectively. Lastly, in vivo induction of CYP3A8 by rifampicin and hyperforin was shown by significant reductions of midazolam exposure that were comparable with those in humans. These results show that the cynomolgus monkey can be a predictive in vivo animal model of PXR-mediated induction of human CYP3A4 and can provide a useful assessment of the resulting pharmacokinetic changes of affected drugs.


Asunto(s)
Citocromo P-450 CYP3A/biosíntesis , Hepatocitos/metabolismo , Macaca fascicularis , Receptores de Esteroides/metabolismo , Xenobióticos/farmacocinética , Adulto , Secuencia de Aminoácidos , Animales , Compuestos Bicíclicos con Puentes/sangre , Compuestos Bicíclicos con Puentes/farmacocinética , Compuestos Bicíclicos con Puentes/farmacología , Línea Celular , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Clonación Molecular , Citocromo P-450 CYP3A/genética , Citocromo P-450 CYP3A/metabolismo , Interacciones Farmacológicas/genética , Inducción Enzimática/efectos de los fármacos , Inducción Enzimática/genética , Femenino , Expresión Génica/efectos de los fármacos , Expresión Génica/genética , Hepatocitos/efectos de los fármacos , Hepatocitos/enzimología , Humanos , Hypericum/química , Macaca mulatta , Masculino , Midazolam/sangre , Midazolam/metabolismo , Midazolam/farmacocinética , Persona de Mediana Edad , Modelos Animales , Datos de Secuencia Molecular , Floroglucinol/análogos & derivados , Floroglucinol/sangre , Floroglucinol/farmacocinética , Floroglucinol/farmacología , Extractos Vegetales/sangre , Extractos Vegetales/farmacocinética , Receptor X de Pregnano , Receptores de Esteroides/genética , Rifampin/sangre , Rifampin/farmacocinética , Rifampin/farmacología , Homología de Secuencia de Aminoácido , Terpenos/sangre , Terpenos/farmacocinética , Terpenos/farmacología , Activación Transcripcional/efectos de los fármacos , Activación Transcripcional/genética , Transfección
9.
Curr Drug Metab ; 10(9): 1055-65, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20214594

RESUMEN

Hypericum perforatum L. (St. John's wort) extracts have gained popularity as an alternative to conventional antidepressant drugs for mild to moderate forms of depressive disorders. New potential psychiatric uses for extracts in obsessive-compulsive disorder, generalised anxiety disorder and alcohol dependence have also been suggested on the basis of animal studies. The neurochemical mechanisms of these central actions are still debated but several components have antidepressant-like and anxiolytic-like effects in animals, or interact with neurotransmitter systems believed to be causally involved in depression, anxiety and in psychiatric illness generally. However, these data should interpreted taking account of the pharmacokinetic data on the main components, particularly those of their brain distribution and concentrations and the relationships with blood concentrations; the (scant) data so far suggest that the acylphloroglucinol hyperforin, the flavonol quercetin and its glycosylated forms and their metabolites, the biflavones amentoflavone and its I3,II8-analog biapigenin and the naphthodianthrones hypericin and pseudohypericin pass the blood-brain barrier poorly in animals. The brain concentrations of all these high-molecular weight, poorly water-soluble compounds after pharmacologically effective doses of the extracts are therefore far below those effective on neurotransmitter receptors and the mechanisms which are obviously important in the central effects of conventional, pharmacologically related drugs. Additional pharmacokinetic data on the brain concentrations of these and other constituents and their metabolites are therefore required for a more meaningful interpretation of the central effects of St. John's Wort extracts.


Asunto(s)
Encéfalo/metabolismo , Hypericum , Preparaciones de Plantas/farmacocinética , Psicotrópicos/farmacocinética , Animales , Ansiolíticos/farmacocinética , Antidepresivos/farmacocinética , Barrera Hematoencefálica/metabolismo , Encéfalo/efectos de los fármacos , Compuestos Bicíclicos con Puentes/farmacocinética , Flavonoles/farmacocinética , Humanos , Nootrópicos/farmacocinética , Permeabilidad , Perileno/farmacocinética , Floroglucinol/análogos & derivados , Floroglucinol/farmacocinética , Preparaciones de Plantas/farmacología , Psicotrópicos/farmacología , Terpenos/farmacocinética
10.
Clin Pharmacokinet ; 45(5): 449-68, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16640452

RESUMEN

Hypericum perforatum (St John's Wort [SJW]) counts among the most favourite herbal drugs, and is the only herbal alternative to classic synthetic antidepressants in the therapy of mild to moderate depression. Several clinical studies have been conducted to verify the effectiveness of ethanolic or methanolic extracts of SJW. Alcoholic SJW extracts are a mixture of substances with widely varying physical and chemical properties and activities. Hyperforin, a phloroglucinol derivative, is the main source of pharmacological effects caused by the consumption of alcoholic extracts of SJW in the therapy of depression. However, several studies indicate that flavone derivatives, e.g. rutin, and also the naphthodianthrones hypericin and pseudohypericin, take part in the antidepressant efficacy. In contrast to the amount of documentation concerning clinical efficacy, oral bioavailability and pharmacokinetic data about the active components are rather scarce. The hyperforin plasma concentration in humans was investigated in a small number of studies. The results of these studies indicate a relevant plasma concentration, comparable with that used in in vitro tests. Furthermore, hyperforin is the only ingredient of H. perforatum that could be determined in the brain of rodents after oral administration of alcoholic extracts. The plasma concentrations of the hypericins were, compared with hyperforin, only one-tenth and, until now, the hypericins could not be found in the brain after oral administration of alcoholic H. perforatum extracts or pure hypericin. Until now, the pharmacokinetic profile of the flavonoids in humans after oral administration of an alcoholic H. perforatum extract has been investigated in only one study. More data are available for rutin and the aglycone quercetin after administration of pure substances or other flavonoid sources.


Asunto(s)
Antidepresivos/farmacocinética , Hypericum/química , Animales , Antracenos , Antidepresivos/farmacología , Compuestos Bicíclicos con Puentes/farmacocinética , Compuestos Bicíclicos con Puentes/farmacología , Ensayos Clínicos como Asunto , Depresión/tratamiento farmacológico , Flavonoides/farmacocinética , Flavonoides/farmacología , Humanos , Perileno/análogos & derivados , Perileno/farmacocinética , Perileno/farmacología , Floroglucinol/análogos & derivados , Floroglucinol/farmacocinética , Floroglucinol/farmacología , Fitoterapia , Extractos Vegetales/farmacocinética , Extractos Vegetales/farmacología , Terpenos/farmacocinética , Terpenos/farmacología
11.
J Clin Psychiatry ; 67(2): 305-9, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16566628

RESUMEN

BACKGROUND: Herbal preparations for depression, such as St. John's wort, are often preferred over pharmaceutical preparations by mothers and midwives after childbirth because these preparations are available to patients as over-the-counter "natural" treatments and are popularly assumed to be safe. The only existing report on St. John's wort excretion into human milk showed that only 1 active component (hyperforin) was detectable in breast milk, but was not detectable in the infants' plasma. Another report found more cases of minor problems in infants breast-fed by women taking St. John's wort. However, significance was reached only in comparison with disease-matched women (p<.01), not healthy controls (p=.20). METHOD: Five mothers who were taking 300 mg of St. John's wort 3 times daily (LI 160 [Jarsin], Lichtwer Pharma GmbH; Berlin, Germany) and their breastfed infants were assessed. Thirty-six breast milk samples (foremilk and hindmilk collected during an 18-hour period) and 5 mothers' and 2 infants' plasma samples were analyzed for hyperforin levels by tandem mass spectrometry (LC/MS/MS; limit of quantification=0.1 ng/mL). Data were gathered from January 2001 to February 2002. RESULTS: Hyperforin is excreted into breast milk at low levels. However, the compound was at the limit of quantification in the 2 infants' plasma samples (0.1 ng/mL). Milk/plasma ratios ranged from 0.04 to 0.13. The relative infant doses of 0.9% to 2.5% indicate that infant exposure to hyperforin through milk is comparable to levels reported in most studies assessing anti-depressants or neuroleptics. No side effects were seen in the mothers or infants. CONCLUSION: These results add to the evidence of the relative safety of St. John's wort while breast-feeding found in previous observational studies.


Asunto(s)
Lactancia Materna , Trastorno Depresivo/tratamiento farmacológico , Hypericum/metabolismo , Leche Humana/química , Floroglucinol/análogos & derivados , Fitoterapia/métodos , Preparaciones de Plantas/farmacocinética , Terpenos/farmacocinética , Adulto , Lactancia Materna/efectos adversos , Compuestos Bicíclicos con Puentes/farmacocinética , Compuestos Bicíclicos con Puentes/uso terapéutico , Trastorno Depresivo/sangre , Trastorno Depresivo/metabolismo , Femenino , Humanos , Hypericum/efectos adversos , Lactante , Espectrometría de Masas , Exposición Materna/efectos adversos , Intercambio Materno-Fetal , Leche Humana/metabolismo , Floroglucinol/farmacocinética , Floroglucinol/uso terapéutico , Fitoterapia/efectos adversos , Preparaciones de Plantas/análisis , Preparaciones de Plantas/sangre , Embarazo , Terpenos/uso terapéutico
12.
Arzneimittelforschung ; 55(10): 561-8, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16294501

RESUMEN

Hypericins, hyperforin and flavonoids are discussed as the main components contributing to the antidepressant action of St. John's wort (Hypericum perforatum). Therefore, the objective of the two open phase I clinical trials was to obtain pharmacokinetic data of these constituents from a hypericum extract containing tablet: hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin. Each trial included 18 healthy male volunteers who received the test preparation, containing 900 mg dry extract of St John's wort (STW 3-VI, Laif 900), either as a single oral dose or as a multiple once daily dose over a period of 14 days. Concentration/time curves were determined for the five constituents, for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing. After single dose intake, the key pharmacokinetic parameters were determined as follows: Hypericin: Area under the curve (AUC(0-infinity)) = 78.33 h x ng/ml, maximum plasma concentration (Cmax) = 3.8 ng/ml, time to reach Cmax (tmax) = 7.9 h, and elimination half-life (t1/2) = 18.71 h; pseudohypericin: AUC(0-infinity) = 97.28 h x ng/ml, Cmax = 10.2 ng/ml, tmax = 2.7 h, t1/2 = 17.19 h; hyperforin: AUC(0-infinity) = 1550.4 h x ng/ml, Cmax = 122.0 ng/ml, tmax = 4.5 h, t1/2 = 17.47 h. Quercetin and isorhamnetin showed two peaks of maximum plasma concentration separated by about 3-3.5 h. Quercetin: AUC(0-infinity) = 417.38 h x ng/ml, Cmax (1) = 89.5 ng/ml, tmax (1) = 1.0 h, Cma (2) = 79.1 ng/ml, tmax (2) = 4.4 h, t1/2 = 2.6 h; isorhamnetin: AUC(0-infinity) = 155.72 h x ng/ml, Cmax (1) = 12.5 ng/ml, tmax (1) = 1.4 h, Cmax (2) = 14.6 ng/ml, tmax (2) = 4.5 h, t1/2 = 5.61 h. Under steady state conditions reached during multiple dose administration similar results were obtained. Further pharmacokinetic characteristics calculated from the obtained data were the mean residence time (MRT), the lag-time, the peak-trough fluctuation (PTF), the lowest observed plasma concentration (Cmin), and the average plasma concentration (Cav). The data obtained for the five consitituents generally corresponded well with values previously published. The trial preparation was well tolerated.


Asunto(s)
Flavonoles/farmacocinética , Hypericum/química , Perileno/análogos & derivados , Floroglucinol/análogos & derivados , Quercetina/farmacocinética , Terpenos/farmacocinética , Adolescente , Adulto , Antracenos , Compuestos Bicíclicos con Puentes/administración & dosificación , Compuestos Bicíclicos con Puentes/efectos adversos , Compuestos Bicíclicos con Puentes/farmacocinética , Flavonoles/administración & dosificación , Flavonoles/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Perileno/administración & dosificación , Perileno/efectos adversos , Perileno/farmacocinética , Floroglucinol/administración & dosificación , Floroglucinol/efectos adversos , Floroglucinol/farmacocinética , Extractos Vegetales/efectos adversos , Extractos Vegetales/análisis , Extractos Vegetales/farmacocinética , Quercetina/administración & dosificación , Quercetina/efectos adversos , Comprimidos , Terpenos/administración & dosificación , Terpenos/efectos adversos
13.
Arzneimittelforschung ; 55(1): 15-22, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-15727160

RESUMEN

The objective of these two open phase I clinical trials was the investigation of the bioavailability of five constituents from a hypericum extract containing tablet, which are discussed as the components contributing to the antidepressant action. Each trial included 18 healthy male volunteers who received the test preparation, containing 612 mg dry extract of St John's wort (STW-3, Laif 600), either as a single oral dose or as a multiple once daily dose over a period of 14 days. Concentration/time curves were determined for hypericin, pseudohypericin, hyperforin, the flavonoid aglycone quercetin, and its methylated form isorhamnetin for 48 h after single dosing and for 24 h on day 14 at the end of 2 weeks of continuous daily dosing. After single dose intake, the key pharmacokinetic parameters were determined as follows: hypericin: area under the curve (AUC(0-infinity)) = 75.96 h x ng/ml, maximum plasma concentration (Cmax) = 3.14 ng/ml, time to reach Cmax (t(max)) = 8.1 h, and elimination half-life (t1/2) = 23.76 h; pseudohypericin: AUC(0-infinity) = 93.03 h x ng/ml, Cmax = 8.50 ng/ml, t(max) = 3.0 h, t1/2 = 25.39 h; hyperforin: AUC(0-max) = 1009.0 h x ng/ml, Cmax = 83.5 nglml, t(max) = 4.4 h, t1/2 = 19.64 h. Quercetin and isohamnetin showed two peaks of maximum plasma concentration separated by about 4 h. Quercetin: AUC(0-infinity) = 318,7 h x ng/ml, Cmax (1) = 47.7 ng/ml, t(max) (1) = 1.17 h, Cmax (2) = 43.8 ng/ml, t(max) (2) = 5.47 h, t1/2 = 4.16 h; isorhamnetin: AUC(0-infinity) = 98.0 h x ng/ml, Cmax (1) = 7.6 ng/ml, t(max) (1) = 1.53 h, Cmax (2) = 9.0 ng/ml, t(max), (2) = 6.42 h, t1/2 = 4.45 h. Under steady state conditions reached during multiple dose administration similar results were obtained. Further pharmacokinetic characteristics calculated from the obtained data were the mean residence time (MRT), the lag-time, the peak-trough fluctuation (PTF), the lowest observed plasma concentration (Cmin), and the average plasma concentration (Cav). The data obtained for hypericin, pseudohypericin and hyperforin generally corresponded well with values previously published, with some deviations observed for the extent of absorption of hypericin and the time course of absorption and elimination of hyperforin. The kinetic characteristics of the hypericum flavonoids are reported here for the first time. The trial preparation was well tolerated.


Asunto(s)
Antidepresivos/farmacocinética , Compuestos Bicíclicos con Puentes/farmacocinética , Flavonoles/farmacocinética , Hypericum/metabolismo , Perileno/análogos & derivados , Perileno/farmacocinética , Floroglucinol/análogos & derivados , Floroglucinol/farmacocinética , Quercetina/farmacocinética , Terpenos/farmacocinética , Adolescente , Adulto , Antracenos , Antidepresivos/efectos adversos , Área Bajo la Curva , Disponibilidad Biológica , Compuestos Bicíclicos con Puentes/efectos adversos , Flavonoles/efectos adversos , Humanos , Hypericum/efectos adversos , Masculino , Persona de Mediana Edad , Perileno/efectos adversos , Floroglucinol/efectos adversos , Extractos Vegetales , Quercetina/efectos adversos , Comprimidos , Terpenos/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA